Association between irisin and metabolic parameters in nondiabetic, nonobese adults: a meta-analysis

Table 1 Characteristics of included studies

Study and year	Location	Study design	Sample size	Male/Female	Health status	Blood sample	ELISA kits	Analysis methods	NOS scores
Armandi A 2022 [56]	Italy	Cross-sectional	41	33/8	NAFLD	Plasma	Phoenix Pharmaceuticals	Spearman	8
Tentolouris A 2018 [46]	Greece	Cross-sectional	53	22/31	Healthy Controls	Plasma	Aviscera Bioscience	Univariate linear regression	7
Foda A. A. 2017a [57]	Egypt	Case–control	40	0/40	PCOS	Serum	BioVendor	Pearson	8
Foda A. A. 2017b [57]	Egypt	Case–control	40	0/40	healthy controls	Serum	BioVendor	Pearson	8
Foda A. A. 2019a [58]	Egypt	Case–control	50	0/50	PCOS	Serum	BioVendor	Pearson	6
Foda A. A. 2019b [58]	Egypt	Case–control	50	0/50	PCOS	Serum	BioVendor	Pearson	6
Jameel F 2015 [47]	Australia	Cross-sectional	49	28/21	healthy	Plasma	Adipogen	Spearman	6
Mehrabian S 2016a [59]	Iran	Case–control	26	0/26	Healthy Controls	Serum	Biovendor	Spearman	8
Mehrabian S 2016b [59]	Iran	Case–control	38	0/38	BF % > 30	Serum	Biovendor	Spearman	8
Rashid FA 2020 [60]	Iraq	Case–control	30	30/0	normal Weight group	Serum	Phoenix Pharmaceuticals	Pearson	6
Anastasilakis AD 2014 [33]	Greece	cross-sectional	122	61/61	healthy	Serum	Phoenix Pharmaceuticals	Spearman	8
Gouni-Berthold I 2013 [35]	Germany	Cross-sectional	72	72/0	mild hypercholesterolemia	Plasma	Aviscera Biosciences	Spearman or Pearson	7
Zhu H 2018 [61]	China	Case–control	40	30/10	healthy	Serum	USCN Life Science Inc	Spearman or Pearson	7
Liu JJ 2013 [19]	Singapore	Case–control	60	25/35	Non-diabetic controls	Plasma	USCN Life Science Inc	Pearson	8

NOS Newcastle–Ottawa Scale, NAFLD nonalcoholic fatty liver disease, PCOS polycystic ovary syndrome, BF% body fat percent

ISSN: 1758-5996